PL2125697T3 - Dodatnio naładowane, rozpuszczalne w wodzie proleki retinoidów i związków podobnych do retinoidów o bardzo wysokich współczynnikach przenikania przez skórę - Google Patents

Dodatnio naładowane, rozpuszczalne w wodzie proleki retinoidów i związków podobnych do retinoidów o bardzo wysokich współczynnikach przenikania przez skórę

Info

Publication number
PL2125697T3
PL2125697T3 PL07700593T PL07700593T PL2125697T3 PL 2125697 T3 PL2125697 T3 PL 2125697T3 PL 07700593 T PL07700593 T PL 07700593T PL 07700593 T PL07700593 T PL 07700593T PL 2125697 T3 PL2125697 T3 PL 2125697T3
Authority
PL
Poland
Prior art keywords
retinoid
retinoids
compounds
positively charged
skin penetration
Prior art date
Application number
PL07700593T
Other languages
English (en)
Inventor
Chongxi Yu
Original Assignee
Yu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yu filed Critical Yu
Publication of PL2125697T3 publication Critical patent/PL2125697T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/20—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by carboxyl groups or halides, anhydrides, or (thio)esters thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C219/10—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the hydroxy groups esterified by a carboxylic acid having the esterifying carboxyl group bound to an acyclic carbon atom of a carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C219/14—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the hydroxy groups esterified by a carboxylic acid having the esterifying carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
PL07700593T 2007-01-15 2007-01-15 Dodatnio naładowane, rozpuszczalne w wodzie proleki retinoidów i związków podobnych do retinoidów o bardzo wysokich współczynnikach przenikania przez skórę PL2125697T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07700593.2A EP2125697B1 (en) 2007-01-15 2007-01-15 Positively charged water-soluble prodrugs of retinoids and retinoid-like compounds with very high skin penetration rates
PCT/IB2007/050122 WO2008087493A1 (en) 2007-01-15 2007-01-15 Positively charged water-soluble prodrugs of retinoids and retinoid-like compounds with very high skin penetration rates

Publications (1)

Publication Number Publication Date
PL2125697T3 true PL2125697T3 (pl) 2017-01-31

Family

ID=39635694

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07700593T PL2125697T3 (pl) 2007-01-15 2007-01-15 Dodatnio naładowane, rozpuszczalne w wodzie proleki retinoidów i związków podobnych do retinoidów o bardzo wysokich współczynnikach przenikania przez skórę

Country Status (11)

Country Link
US (5) US9193672B2 (pl)
EP (2) EP2125697B1 (pl)
JP (1) JP5826459B2 (pl)
CN (4) CN107652212B (pl)
CA (2) CA2972344C (pl)
DK (1) DK2125697T3 (pl)
ES (1) ES2596857T3 (pl)
HU (1) HUE031712T2 (pl)
PL (1) PL2125697T3 (pl)
PT (1) PT2125697T (pl)
WO (1) WO2008087493A1 (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090221703A1 (en) 2006-07-09 2009-09-03 Chongxi Yu High penetration composition and uses thereof
US20090238763A1 (en) 2006-07-09 2009-09-24 Chongxi Yu High penetration compositions and uses thereof
EP2091914A4 (en) 2006-11-08 2010-12-29 Chongxi Yu TRANSDERMAL ADMINISTRATION SYSTEMS FOR PEPTIDES AND RELATED CONNECTIONS
JP2010529101A (ja) 2007-06-04 2010-08-26 テックフィールズ インコーポレイテッド 非常に速い皮膚及び膜浸透速度を有するｎｓａｉａプロドラッグ及びその新規医薬使用
CN108191846B (zh) 2008-12-04 2021-08-20 于崇曦 高穿透性组合物及其应用
EP2660247A3 (en) * 2009-05-08 2014-09-03 Chongxi Yu High penetration prodrug compositions of peptides and peptide-related compounds
RU2546005C2 (ru) 2009-09-15 2015-04-10 Кью Эл Ти ИНК. Фармацевтические составы, содержащие 9-цис-ретиниловые сложные эфиры в липидном наполнителе
SG10201507819VA (en) 2010-04-19 2015-10-29 Quadra Logic Tech Inc Therapeutic Regimen And Methods For Treating Or Ameliorating Visual Disorders Associated With An Endogenous Retinoid Deficiency
WO2012125724A1 (en) * 2011-03-14 2012-09-20 Beth Israel Deaconess Medical Center Methods and compositions for the treatment of proliferative disorders
JP2014527083A (ja) 2011-09-15 2014-10-09 アリゾナ ボード オブ リージェンツ， ア ボディー コーポレイト オブ ザ ステート オブ アリゾナ， アクティング フォー アンド オン ビハーフ オブ アリゾナ ステート ユニバーシティー 治療用化合物
CN102503908B (zh) * 2011-11-22 2013-09-04 江苏省原子医学研究所 维a酸衍生物、其制备方法、其药物组合物及其在制备抗肿瘤药物中的应用
AU2013232697B2 (en) 2012-03-01 2017-10-19 Eluminex Biosciences (Suzhou) Limited Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency
EP2858648B1 (en) 2012-06-07 2018-08-22 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the inhibition of pin1
EP2869717B8 (en) * 2012-07-09 2018-07-25 NoGlo, Inc. Prevention of alcohol reaction with dietary supplements
WO2014161011A1 (en) * 2013-03-26 2014-10-02 Realitygate (Pty) Ltd Distortion viewing with improved focus targeting
US10372204B2 (en) * 2013-10-30 2019-08-06 Technology Against Als Communication and control system and method
WO2015109318A2 (en) 2014-01-17 2015-07-23 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Therapeutic methods
WO2016011265A2 (en) 2014-07-17 2016-01-21 Beth Israel Deaconess Medical Center, Inc. Biomarkers for pin1-associated disorders
WO2016011268A1 (en) 2014-07-17 2016-01-21 Beth Israel Deaconess Medical Center, Inc. Atra for modulating pin1 activity and stability
US10548864B2 (en) 2015-03-12 2020-02-04 Beth Israel Deaconess Medical Center, Inc. Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions
US10238655B2 (en) 2017-01-23 2019-03-26 Arizona Board Of Regents On Behalf Of Arizona State University Dihydroindene and tetrahydronaphthalene compounds
US10238626B2 (en) 2017-01-23 2019-03-26 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
US10231947B2 (en) 2017-01-23 2019-03-19 Arizona Board Of Regents On Behalf Of Arizona State University Isochroman compounds and methods of use thereof
EP3802507A1 (en) * 2018-05-30 2021-04-14 Translate Bio, Inc. Vitamin cationic lipids
WO2020257064A1 (en) * 2019-06-20 2020-12-24 Butzloff Peter Robert Fullerenol xanthophyll adducts and methods
CN119925334B (zh) * 2023-11-06 2026-06-12 南京毓浠医药技术有限公司 一种含有氨甲环酸与维a酸的复方组合物

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH393310A (de) * 1959-09-23 1965-06-15 Hoffmann La Roche Verfahren zur Herstellung von stabilen Vitamin-A-Estern
US3950418A (en) * 1970-02-02 1976-04-13 Hoffmann-La Roche Inc. Vitamin A acid amides
US4224244A (en) * 1973-03-30 1980-09-23 Hoffmann-La Roche Inc. 9-Phenyl 5,6-dimethyl-nona-2,4,6,8 tetraenal or tetraenol derivatives
US4326055A (en) * 1977-12-22 1982-04-20 Hoffmann-La Roche Inc. Stilbene derivatives
DK159967C (da) * 1977-12-22 1991-06-03 Hoffmann La Roche Analogifremgangsmaade til fremstilling af terapeutisk aktive stilbenderivater
FR2542998B1 (fr) 1983-03-24 1986-01-31 Rhone Poulenc Sante Nouvelle forme transdermale du dinitrate d'isosorbide
US4588525A (en) * 1984-02-27 1986-05-13 Molecular Biosystems, Inc. Prodrug compounds for dermal application
US4677120A (en) 1985-07-31 1987-06-30 Molecular Design International Topical prodrugs for treatment of acne and skin diseases
ZA877325B (en) * 1986-10-06 1988-04-07 F. Hoffmann-La Roche & Co. Aktiengesellschaft Novel retinoids
DK498487A (da) 1986-10-06 1988-04-07 Hoffmann La Roche Hidtil ukendte retinoider
US5264578A (en) 1987-03-20 1993-11-23 Allergan, Inc. Disubstituted acetylenes bearing heterobicyclic groups and heteroaromatic or phenyl groups having retinoid like activity
JP2672363B2 (ja) * 1989-03-29 1997-11-05 帝人株式会社 有機非線形光学材料
US5399561A (en) 1989-09-19 1995-03-21 Allergan, Inc. Acetylenes disubstituted with a phenyl or heteroaryl group and a 2-oxochromanyl, 2-oxothiochromanyl or 2-oxo-1,2,3,4-tetrahydro-quinolinyl group having retinoid-like biological activity
US5272156A (en) 1989-09-19 1993-12-21 Allergan, Inc. Acetylenes disubstituted with a heteroaromatic group and a 2-substituted 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity
US5264456A (en) 1989-12-29 1993-11-23 Allergan, Inc. Acetylenes disubstituted with a furyl group and a substituted phenyl group having retinoid like activity
US5648563A (en) 1991-04-09 1997-07-15 Sloan-Kettering Institute For Cancer Research Retro-alpha-retinol derivative and uses of retro-alpha-retinol
DE69224294T2 (de) 1991-10-16 1998-08-20 Richardson Vicks Inc Verbesserte hautpenetrationssysteme fuer erhoehte topische freisetzung von arzneimitteln
EP0626955A1 (en) 1992-02-11 1994-12-07 Allergan, Inc. Heteroaryl substituted phenylethenyl compounds having retinoid-like biological activity
US6320074B1 (en) * 1992-04-22 2001-11-20 Ligand Pharmaceuticals Incorporated Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
US5455265A (en) 1993-02-11 1995-10-03 Allergan, Inc. Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors
US5399586A (en) 1993-03-11 1995-03-21 Allergan, Inc. Treatment of mammals afflicted with tumors with compounds having RXR retinoid receptor agonist activity
US5475022A (en) 1993-10-18 1995-12-12 Allergan, Inc. Phenyl or heteroaryl and tetrahydronaphthyl substituted diene compounds having retinoid like biological activity
US5451605A (en) 1993-12-30 1995-09-19 Allergan, Inc. 1,2-epoxycyclohexanyl and bicyclic aromatic substituted ethyne compounds having retinoid-like biological activity
US5470999A (en) 1993-12-30 1995-11-28 Allergan, Inc. Cyclohexene and bicyclic aromatic substituted ethyne compounds having retinoid-like biological activity
US5426118A (en) 1993-12-30 1995-06-20 Allergan, Inc. [4-(1,2-epoxycyclohexanyl)but-3-en-1-ynyl]aromatic and heteroaromatic acids and derivatives having retinoid-like biological activity
US5648385A (en) 1994-01-03 1997-07-15 Bristol-Myers Squibb Co. Retinoid-like compounds
US5498755A (en) 1994-08-23 1996-03-12 Chandraratna; Roshantha A. Disubstituted aryl and heteroaryl imines having retinoid-like biological activity
US5556996A (en) 1994-12-29 1996-09-17 Allergan Oxiranyls disubstituted with a phenyl group and a substituted chromanyl or tetrahydroquinolinyl group having retinoid like activity
US5837728A (en) * 1995-01-27 1998-11-17 Molecular Design International 9-cis retinoic acid esters and amides and uses thereof
US5559248A (en) 1995-04-05 1996-09-24 Bristol-Myers Squibb Co. Retinoid-like heterocycles
US5616712A (en) 1995-05-16 1997-04-01 Allergan Acetylenes disubstituted with a phenyl or heteroaryl group and a 2-thio-1,2,3,4-tetrahdroquinolinyl, 2-alkylthio-3,4-dihydroquinolinyl or 2-alkoxy-3,4-dihydroquinolinyl group having retinoid-like biological activity
DE19523079A1 (de) * 1995-06-26 1997-01-02 Basf Ag Ester und Amide der 9(Z)-Retinsäure
WO1998001138A1 (fr) 1996-07-04 1998-01-15 Nippon Kayaku Kabushiki Kaisha Injections de succinate sodique de methylprednisolone
US6462064B1 (en) * 1996-07-08 2002-10-08 Galderma Research & Development S.N.C. Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents, especially for cervical cancers and dysplasias
US6127415A (en) * 1996-07-08 2000-10-03 Galderma Research & Development, S.N.C. Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents
DE19631685A1 (de) * 1996-08-06 1998-02-12 Wella Ag Hydrolytisch spaltbare Wirkstoffderivate, diese enthaltene Haarbehandlungsmittel und Verfahren zum Behandeln von Haaren
US6011049A (en) 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
EP1126838A4 (en) 1998-10-30 2005-02-16 Nitromed Inc NITROSIS AND NITROSYAL NON-STEROID ANTI-INFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE
SE9900941D0 (sv) * 1998-12-23 1999-03-16 Nomet Management Serv Bv Novel retinoic acid derivatives and their use
AU3770600A (en) * 1999-04-06 2000-10-23 Bristol-Myers Squibb Company Selective retinoic acid analogs
US6417207B1 (en) 1999-05-12 2002-07-09 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
US6310262B1 (en) 1999-10-18 2001-10-30 Basilea Pharmaceutica Ag Process for preparing retiferol derivatives
US6693135B2 (en) 2000-01-10 2004-02-17 Nexmed (Holdings) Incorporated Prostaglandin compositions and methods of treatment for male erectile dysfunction
FR2804323B1 (fr) * 2000-01-31 2006-07-07 Galderma Res & Dev Utilisation de composes de type retinoides en tant qu'agents anti-bacteriens
WO2003022270A1 (en) 2001-09-13 2003-03-20 Noven Pharmaceuticals, Inc. Transdermal administration of an enalapril ester
CN100360502C (zh) * 2002-07-23 2008-01-09 阿登尼亚投资有限公司 视黄醇衍生物、它们在治疗癌症和增强其它细胞毒性剂功效中的应用
BRPI0408223A (pt) 2003-03-12 2006-03-01 Celgene Corp composto, isÈmeros, composição farmacêutica, e, métodos de inibir pde4 e mmp, de modular a produção de tnf-alfa em um mamìfero e de tratar, previnir ou controlar uma doença ou condição
US7052715B2 (en) 2003-04-11 2006-05-30 All Natural Fmg, Inc. Alcohol-free transdermal analgesic composition and processes for manufacture and use thereof
AU2004293477A1 (en) 2003-11-25 2005-06-09 University Of Rochester Compounds for delivering amino acids or peptides with antioxidant activity into mitochondria and use thereof
EP1905456A4 (en) 2005-07-06 2010-12-22 Seikagaku Kogyo Co Ltd PHARMACEUTICAL LIGHT-NETWORKED HYALURONIC DERIVATIVE GEL
AU2006346195B2 (en) 2006-07-09 2013-03-07 Techfields Biochem Co. Ltd Positively charged water-soluble prodrugs of aspirin
HUE033687T2 (en) 2006-07-18 2017-12-28 Techfields Biochem Co Ltd Ibuprofen positively charged water soluble prodrugs with very fast skin penetration rates
PL2046727T3 (pl) 2006-07-25 2014-08-29 Techfields Biochem Co Ltd Dodatnio naładowane rozpuszczalne w wodzie proleki diklofenaku o bardzo szybkim stopniu przenikania przez skórę
CN101500983B (zh) 2006-07-26 2015-09-16 于崇曦 具有快速皮肤穿透速度的带正电荷的水溶性二氟尼柳及相关化合物的前药
PT2049482E (pt) 2006-08-08 2016-02-24 Techfields Biochem Co Ltd Profármacos solúveis em água carregados positivamente de ácidos aril- e heteroarilacéticos com velocidade de penetração na pele muito rápida
US8458932B2 (en) 2006-08-11 2013-06-11 Alameda Technology, Llc Optical illusion device
EP2054384A4 (en) 2006-08-15 2010-11-03 Techfields Biochem Co Ltd POSITIVELY LOADED WATER-SOLUBLE PRODRUGS OF ARYL AND HETEROARYLPROPIONIC ACIDS WITH A VERY FAST SKIN PUNCHING RATE
WO2008026776A1 (en) 2006-08-31 2008-03-06 Nanocarrier Co., Ltd. Transdermal composition, transdermal pharmaceutical composition and transdermal cosmetic composition comprising polymer micelle encapsulating active ingredient
EP3388417A1 (en) 2006-09-03 2018-10-17 Techfields Biochem Co. Ltd Positively charged water-soluble prodrugs of acetaminophen and related compounds with very fast skin penetration rate
PL2084132T3 (pl) 2006-09-03 2019-03-29 Techfields Biochem Co. Ltd Dodatnio naładowane rozpuszczalne w wodzie proleki z kwasów n-arylantranilowych z bardzo szybką penetracją skóry
EP2084165B1 (en) 2006-10-11 2013-06-12 Techfields Biochem Co. Ltd Positively charged water-soluble prodrugs of oxicams and related compounds with very high skin penetration rate
WO2008093173A1 (en) 2007-01-31 2008-08-07 Chongxi Yu Positively charged water-soluble prodrugs of 1h-imidazo[4, 5-c]quinolin-4-amines and related compounds with very high skin penetration rates
JP2010529101A (ja) 2007-06-04 2010-08-26 テックフィールズ インコーポレイテッド 非常に速い皮膚及び膜浸透速度を有するｎｓａｉａプロドラッグ及びその新規医薬使用

Also Published As

Publication number Publication date
WO2008087493A1 (en) 2008-07-24
US20240156770A1 (en) 2024-05-16
CN101605754B (zh) 2015-09-16
HK1222842A1 (zh) 2017-07-14
EP2125697B1 (en) 2016-09-28
ES2596857T3 (es) 2017-01-12
JP5826459B2 (ja) 2015-12-02
CN113636966A (zh) 2021-11-12
CA2674822C (en) 2017-08-01
JP2010515716A (ja) 2010-05-13
CN113636966B (zh) 2024-01-12
US9193672B2 (en) 2015-11-24
US20100010084A1 (en) 2010-01-14
CA2972344A1 (en) 2008-07-24
CN109503446A (zh) 2019-03-22
CA2972344C (en) 2021-10-26
PT2125697T (pt) 2016-10-18
HK1137413A1 (en) 2010-07-30
DK2125697T3 (en) 2016-11-14
EP3181132A1 (en) 2017-06-21
US20210196664A1 (en) 2021-07-01
HUE031712T2 (en) 2017-08-28
CN109503446B (zh) 2021-08-20
CA2674822A1 (en) 2008-07-24
EP2125697A4 (en) 2010-10-27
CN101605754A (zh) 2009-12-16
US20160184253A1 (en) 2016-06-30
CN107652212A (zh) 2018-02-02
US11786497B2 (en) 2023-10-17
CN107652212B (zh) 2019-11-15
US20170072060A1 (en) 2017-03-16
EP2125697A1 (en) 2009-12-02

Similar Documents

Publication Publication Date Title
PT2125697T (pt) Pró-fármacos solúveis em água positivamente carregados de retinóides e compostos tipo retinóide com taxas de penetração na pele muito altas
PL2061749T3 (pl) Dodatnio naładowane, rozpuszczalne w wodzie proleki acetaminofenu i związków pokrewnych o bardzo dużej szybkości przenikania przez skórę
EP2046727A4 (en) POSITIVELY LOADED, WATER-SOLUBLE PRODRUGS FROM DICLOFENAC WITH VERY FAST SKIN PENETRATION SPEED
PL2041068T3 (pl) Dodatnio naładowane rozpuszczalne w wodzie proleki ibuprofenu o bardzo dużych prędkościach przenikania przez skórę
ZA201003625B (en) 5-anilinoimidazopyridines and methods of use
ZA201008483B (en) Diazacarbazoles and methods of use
GB201102311D0 (en) Methods and apparatus related to management of experiments
IL213547A0 (en) Compounds and methods of use
EP2640287A4 (en) Tissue removal device and method of use
EP2350770A4 (en) PROCESS FOR CONSCIOUS PERFORMANCE MANAGEMENT
EP2126589A4 (en) METABOLISM AND DIABETIC SUFFERING AND METHOD OF USE THEREOF
IL209383A0 (en) Carbonate prodrugs and methods of using the same
IL206125A0 (en) Azaindolizines and methods of use
IL207631A0 (en) Postsynaptically targeted chemodenervation agents and their methods of use
IL209548A0 (en) Diazacarbazoles and methods of use
EP2605861A4 (en) FINE PARTICLE APPLICATOR AND ASSOCIATED METHODS
WO2009155116A9 (en) Methods of reducing pain and inflammation
PL2084124T3 (pl) Dodatnio naładowane rozpuszczalne w wodzie proleki prostaglandyn i związków pokrewnych o bardzo dużych szybkościach przenikania przez skórę
EP3363437B8 (en) Aminoindane compounds and use thereof in treating pain
PL2084132T3 (pl) Dodatnio naładowane rozpuszczalne w wodzie proleki z kwasów n-arylantranilowych z bardzo szybką penetracją skóry
ZA201102518B (en) Modified release formulation and methods of use
PL2049482T3 (pl) Dodatnio naładowane rozpuszczalne w wodzie proleki kwasów arylo- i heteroarylooctowych o bardzo dużej szybkości przenikania przez skórę
EP2084165A4 (en) PRO-DRUGS OF WATER-SOLUBLE OXICAMS POSITIVE AND RELATED COMPOUNDS WITH VERY HIGH SKIN PENETRATION SPEED
EP2077991A4 (en) POSITIVELY LOADED, WATER-SOLUBLE PRODRUGS OF LOTS AND RELATED COMPOUNDS WITH VERY HIGH SKIN PENETRATION RATES
ZA201202877B (en) Equipment and method of application of fungicides having maximum and constant efficacy with zero waste